Luc G.T. Morris - Concepedia

Author

Luc G.T. Morris

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

L G Morris, L G T Morris, L Morris, L. G. Morris, L. Morris, L.G. Morris, L.G.T. Morris, LUC G.T. MORRIS, LUC MORRIS, Leon Morris

655

Publications

35.4K

Citations

H-Index

147

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center New York University Cornell University Icahn School of Medicine at Mount Sinai Molecular Oncology (United States)

About

Luc G.T. Morris is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cancer research, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	63	19.1K
2	Health Sciences	14	15	4.5K
3	Arts	1	1	57
4	Education	1	1	63
5	Law	1	1	60

Luc G.T. Morris

183

Publications

31.8K

Citations

H-Index

Page 1

	Year	Citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Nature Genetics Cancer ImmunosurveillanceTumor HeterogeneityMedicineImmunologyPathology	2019	4.2K
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Ahmet Zehir, Ryma Benayed, Ronak Shah, Nature Medicine Metastatic CancerOncologySomatic VariantMutational LandscapeTumor Heterogeneity	2017	3.4K
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Cell Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor	2017	2.5K
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Şevin Turcan, Daniel Rohle, Anuj Goenka, Nature Neuro-oncologySomatic VariantTumor HeterogeneityMedicineGenetics	2012	1.9K
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Diego Chowell, Luc G.T. Morris, Claud Grigg, Science	2017	1.1K
The head and neck cancer immune landscape and its immunotherapeutic implications Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard, JCI Insight	2016	773
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Bastien Nguyen, Christopher J. Fong, Anisha Luthra, Cell UrologyTumor HeterogeneityMedicineNext-generation SequencingPathology	2022	608
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response Rajarsi Mandal, Robert Samstein, Ken-Wing Lee, Science ImmunodeficienciesImmunologyPathologyMismatch Repair DeficiencyImmunotherapy	2019	564
The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care Luc G.T. Morris, Andrew G. Sikora, Tor D. Tosteson, Thyroid	2013	512
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway Zhiqiang Li, Pedram Razavi, Qing Li, Cancer Cell Tumor BiologyHippo PathwaySignaling PathwayMedicineCdk4/6 Inhibitors	2018	491

Page 1